Collaborative Research Inc. (NASDAQ:CRIC) of Waltham, Mass.,received a $500,000, two-year Phase II small businessinnovation research (SBIR) grant from the National Institute ofGeneral Medical Sciences to develop a multiplex DNA diagnostictest technology. The initial target will be for multiple mutantalleles of the CFTR gene that is responsible for cystic fibrosis.

(c) 1997 American Health Consultants. All rights reserved.